香加皮提取物抗肿瘤活性的研究  

Anti-tumor Activity of Extract from Periploca Sepium Bge

作　　者：张静[1] 单保恩[1] 刘刚叁[2] 赵学涛[1] 陈书红[2] 

机构地区：[1]河北医科大学第四医院科研中心,河北石家庄050011 [2]华北制药集团新药研究开发有限责任公司,河北石家庄050015

出　　处：《癌变．畸变．突变》2006年第2期108-111,共4页Carcinogenesis,Teratogenesis & Mutagenesis

基　　金：国家自然科学基金项目(No.3037153);河北省自然科学基金项目(No.C2004000610)

摘　　要：背景与目的研究中药香加皮提取物的抗肿瘤活性,探讨其抗肿瘤机制。材料与方法采用噻唑蓝(3-[4,5-di methylthiazol-2-yl]-2,5diphenyltetrazoliumbromide,MTT)法观察香加皮醇提物和水提物对MCF-7、TE-13、QG56、SMMC7721、T24、Hela、K562等肿瘤细胞增殖的抑制作用,应用流式细胞术检测肿瘤细胞的周期变化和对凋亡的影响。结果香加皮醇提物和水提物均能明显抑制多种肿瘤细胞的增殖,呈浓度依赖性;醇提物的抑瘤作用(IC50<10μg/ml)强于水提物(IC50<40μg/ml),并且差异具有统计学意义(P<0.05)。香加皮醇提物可将MCF-7细胞阻滞于G0/G1期,并呈时间依赖性地诱导MCF-7细胞发生凋亡。10μg/ml香加皮醇提物作用MCF-7细胞24h,与对照组相比,G0/G1期细胞显著增多,作用48h,凋亡率从对照组的0.70%±0.13%升高到13.54%±2.12%,两者之间的差异有统计学意义(P<0.05)。结论香加皮提取物对体外肿瘤细胞的增殖具有显著的抑制作用,醇提物强于水提物,其抗瘤机制可能与阻滞肿瘤细胞周期和诱导凋亡有关。BACKGROUND ＆ AIM： To investigate the anti-tumor activity of extract from Periploca Sepium Bge （PSBE） and to study its probable mechanisms. MATERIALS AND METHODS： The growth-inhibitory effect of ethanol extract from Periploca sepium bge （PSBEE） and water extract from Periploca sepium Bge （PSBWE） on MCF-7, TE-13, QG56, SMMC7721, T24, Hela, K562 tumor cell lines were examined by using MTT assay, the change of cell cycle and the induction of apoptosis were analyzed with flow cytometry. RESULTS： Both PSBEE and PSBWE could significantly inhibit the proliferation of tumor cell lines, the effect was dose-dependent, PSBEE （IC50〈 10μg/ml） was more effective than PSBWE （IC50〈 40μg/ml）. PSBEE could arrest the cell cycle at G0/G1 phase and induce apoptosis in MCF-7 cells in a time-dependent manner. The proportion of tumor cells in the G0/G1 phase increased after treatment with 10μg/ml PSBEE for 24 hours, the apoptotic rate reached 13.54% ± 2.12% after 48 h. CONCLUSION： Cell growth in vitro was inhibited significanttly by extract from Periploca sepium Bge, PSBEE might exert its anti-tumor activity by blocking the cell cycle and inducing apoptosis of tumor cells.

关 键 词：香加皮 抗肿瘤 细胞增殖 细胞周期 细胞凋亡 

分 类 号：R730.52[医药卫生—肿瘤]